Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Consultant-Needed-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Takeda Pharmaceutical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing...

              Contact the Supplier

              Lead Product(s): Lanadelumab

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 06, 2020

              Details:

              Data from the Phase 3 HELP Study™ Open-label Extension suggest that TAKHZYRO® (lanadelumab) is well-tolerated and can prevent hereditary angioedema (HAE) attacks over an extended treatment period, with sustained and consistent reduction in monthly attack rates.

              Takeda Pharmaceutical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Takeda Gets Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO for Preventive Treatment for Hereditary Angioedema Attacks

              Contact the Supplier

              Lead Product(s): Lanadelumab

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 29, 2020

              Details:

              The pre-filled syringe presentation is designed to enhance the treatment administration experience for HAE patients receiving TAKHZYRO.

              PharmaCompass__DigitalAd